Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
These Stocks Are Moving the Most Today: Roivant Sciences, Textainer, Okta, Microsoft, Alphabet
2023-10-23 04:44
Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
You Might Like...
Nasa holds first public meeting about sightings of UFOs
Facebook down: Social network not working as users stopped from posting
CarbonCapture Inc. Awarded as 2023 Technology Pioneer by World Economic Forum
The Standard Names Dave Friesen Second Vice President of Enterprise Data and Analytics
Hurricane Idalia Exposes Florida’s Dangerous Flood Insurance Gap
Facebook and Instagram to block news in Canada
Police use AI camera van to spot drivers using mobile phones
The most popular search engine in the world is about to look different